183 related articles for article (PubMed ID: 24432019)
1. Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice.
Liu CL; Ye P; Lin J; Butts CL; Miao CH
Front Immunol; 2014 Jan; 4():502. PubMed ID: 24432019
[TBL] [Abstract][Full Text] [Related]
2. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
3. The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice.
Liu CL; Lyle MJ; Shin SC; Miao CH
Data Brief; 2016 Jun; 7():973-80. PubMed ID: 27081675
[TBL] [Abstract][Full Text] [Related]
4. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
Liu CL; Ye P; Yen BC; Miao CH
Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
[TBL] [Abstract][Full Text] [Related]
5. Strategies to target long-lived plasma cells for treating hemophilia A inhibitors.
Liu CL; Lyle MJ; Shin SC; Miao CH
Cell Immunol; 2016 Mar; 301():65-73. PubMed ID: 26877251
[TBL] [Abstract][Full Text] [Related]
6. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.
Miao CH
Expert Rev Hematol; 2010 Aug; 3(4):469-83. PubMed ID: 20976115
[TBL] [Abstract][Full Text] [Related]
8. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
Zhang AH; Skupsky J; Scott DW
Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
[TBL] [Abstract][Full Text] [Related]
9. Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors.
Doshi BS; Raffini LJ; George LA
J Thromb Haemost; 2020 Apr; 18(4):848-852. PubMed ID: 31985872
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
11. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
13. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice.
Smith BM; Lyle MJ; Chen AC; Miao CH
J Thromb Haemost; 2020 Feb; 18(2):328-340. PubMed ID: 31609041
[TBL] [Abstract][Full Text] [Related]
15. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
16. Reprogrammed CD4
Herzog RW; Kuteyeva V; Saboungi R; Terhorst C; Biswas M
Front Immunol; 2019; 10():274. PubMed ID: 30842776
[TBL] [Abstract][Full Text] [Related]
17. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
18. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
19. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer.
Qian J; Burkly LC; Smith EP; Ferrant JL; Hoyer LW; Scott DW; Haudenschild CC
Eur J Immunol; 2000 Sep; 30(9):2548-54. PubMed ID: 11009088
[TBL] [Abstract][Full Text] [Related]
20. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.
Rossi G; Sarkar J; Scandella D
Blood; 2001 May; 97(9):2750-7. PubMed ID: 11313267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
